- Home
- MMI vs ARVN Comparison
MMI vs ARVN Comparison
Compare MMI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- ARVN
- Stock Information
- Founded
- MMI 1971
- ARVN 2015
- Country
- MMI United States
- ARVN United States
- Employees
- MMI N/A
- ARVN N/A
- Industry
- MMI Real Estate
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- ARVN Health Care
- Exchange
- MMI Nasdaq
- ARVN Nasdaq
- Market Cap
- MMI 1.6B
- ARVN 1.7B
- IPO Year
- MMI 2013
- ARVN 2018
- Fundamental
- Price
- MMI $40.62
- ARVN $24.43
- Analyst Decision
- MMI Sell
- ARVN Strong Buy
- Analyst Count
- MMI 1
- ARVN 13
- Target Price
- MMI $30.00
- ARVN $61.08
- AVG Volume (30 Days)
- MMI 89.1K
- ARVN 702.9K
- Earning Date
- MMI 11-08-2024
- ARVN 10-30-2024
- Dividend Yield
- MMI 1.25%
- ARVN N/A
- EPS Growth
- MMI N/A
- ARVN N/A
- EPS
- MMI N/A
- ARVN N/A
- Revenue
- MMI $622,225,000.00
- ARVN $161,100,000.00
- Revenue This Year
- MMI N/A
- ARVN $237.44
- Revenue Next Year
- MMI $26.79
- ARVN N/A
- P/E Ratio
- MMI N/A
- ARVN N/A
- Revenue Growth
- MMI N/A
- ARVN 1.07
- 52 Week Low
- MMI $29.93
- ARVN $20.99
- 52 Week High
- MMI $44.24
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- MMI 54.56
- ARVN 38.64
- Support Level
- MMI $39.77
- ARVN $21.17
- Resistance Level
- MMI $41.53
- ARVN $28.70
- Average True Range (ATR)
- MMI 1.15
- ARVN 1.55
- MACD
- MMI -0.05
- ARVN -0.55
- Stochastic Oscillator
- MMI 50.19
- ARVN 21.87
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a leading national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.